• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性肝癌三维适形放疗中放射性肝病的危险因素及肝脏放射耐受性

Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance.

作者信息

Liang Shi-Xiong, Zhu Xiao-Dong, Xu Zhi-Yong, Zhu Ji, Zhao Jian-Dong, Lu Hai-Jie, Yang Yun-Li, Chen Long, Wang An-Yu, Fu Xiao-Long, Jiang Guo-Liang

机构信息

Department of Radiation Oncology, Fudan University Cancer Hospital, Shanghai, China.

出版信息

Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):426-34. doi: 10.1016/j.ijrobp.2005.12.031.

DOI:10.1016/j.ijrobp.2005.12.031
PMID:16690430
Abstract

PURPOSE

To identify risk factors relevant to radiation-induced liver disease (RILD) and to determine the hepatic tolerance to radiation.

METHODS AND MATERIALS

The data of 109 primary liver carcinomas (PLC) treated with hypofractionated three-dimensional conformal radiation therapy (3D-CRT) were analyzed. Seventeen patients were diagnosed with RILD and 13 of 17 died of it.

RESULTS

The risk factors for RILD were late T stage, large gross tumor volume, presence of portal vein thrombosis, association with Child-Pugh Grade B cirrhosis, and acute hepatic toxicity. Multivariate analyses demonstrated that the severity of hepatic cirrhosis was a unique independent predictor. For Child-Pugh Grade A patients, the hepatic radiation tolerance was as follows: (1) Mean dose to normal liver (MDTNL) of 23 Gy was tolerable. (2) For cumulative dose-volume histogram, the tolerable volume percentages would be less than: V5 of 86%, V10 of 68%, V15 of 59%, V20 of 49%, V25 of 35%, V30 of 28%, V35 of 25%, and V40 of 20%. (3) Tolerable MDTNL could be estimated by MDTNL (Gy) = -1.686 + 0.023 * normal liver volume (cm3).

CONCLUSION

The predominant risk factor for RILD was the severity of hepatic cirrhosis. The hepatic tolerance to radiation could be estimated by dosimetric parameters.

摘要

目的

确定与放射性肝病(RILD)相关的危险因素,并确定肝脏对辐射的耐受性。

方法和材料

分析了109例接受大分割三维适形放射治疗(3D-CRT)的原发性肝癌(PLC)患者的数据。17例患者被诊断为RILD,其中13例死于该病。

结果

RILD的危险因素包括T分期较晚、肿瘤大体体积较大、存在门静脉血栓形成、合并Child-Pugh B级肝硬化以及急性肝毒性。多因素分析表明,肝硬化的严重程度是唯一的独立预测因素。对于Child-Pugh A级患者,肝脏的辐射耐受性如下:(1)正常肝脏平均剂量(MDTNL)23 Gy是可耐受的。(2)对于累积剂量体积直方图,可耐受的体积百分比应小于:V5为86%,V10为68%,V15为59%,V20为49%,V25为35%,V30为28%,V35为25%,V40为20%。(3)可通过MDTNL(Gy)=-1.686 + 0.023×正常肝脏体积(cm³)估算可耐受的MDTNL。

结论

RILD的主要危险因素是肝硬化的严重程度。肝脏对辐射的耐受性可通过剂量学参数进行估算。

相似文献

1
Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance.原发性肝癌三维适形放疗中放射性肝病的危险因素及肝脏放射耐受性
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):426-34. doi: 10.1016/j.ijrobp.2005.12.031.
2
Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma.莱曼正常组织并发症概率模型在原发性肝癌三维适形放射治疗中对放射性肝病的预测
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):189-95. doi: 10.1016/j.ijrobp.2005.11.034. Epub 2006 Mar 20.
3
Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease.接受放射治疗的肝细胞癌患者对放射性肝病的生物学易感性。
Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1502-9. doi: 10.1016/j.ijrobp.2004.05.048.
4
Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma.原发性肝癌的大分割三维适形放射治疗
Cancer. 2005 May 15;103(10):2181-8. doi: 10.1002/cncr.21012.
5
Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease.将生物学因素纳入放射性肝病平行结构正常组织并发症概率模型。
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1150-6. doi: 10.1016/j.ijrobp.2004.12.031.
6
Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy.预测接受三维适形放疗的不可切除肝细胞癌患者放射性肝毒性的剂量-体积参数。
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):225-31. doi: 10.1016/j.ijrobp.2006.08.015. Epub 2006 Oct 23.
7
Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child-Pugh Grade A cirrhosis.基于 Child-Pugh 分级 A 肝硬化的原发性肝癌患者行适形分割放疗后,放射性肝损伤的剂量预测因子识别。
Radiother Oncol. 2011 Feb;98(2):265-9. doi: 10.1016/j.radonc.2010.10.014. Epub 2010 Nov 4.
8
[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma].三维适形放疗联合经动脉化疗栓塞治疗肝细胞癌
Zhonghua Zhong Liu Za Zhi. 2006 Mar;28(3):222-6.
9
[Prognostic factor of primary liver cancer treated by hypofractionated three-dimensional conformal radiotherapy].[三维适形放疗大分割治疗原发性肝癌的预后因素]
Zhonghua Zhong Liu Za Zhi. 2005 Oct;27(10):613-5.
10
Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication.肝细胞癌患者三维适形放疗后放射性肝病:剂量学分析及意义
Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):156-62. doi: 10.1016/s0360-3016(02)02915-2.

引用本文的文献

1
Carbon-Ion Radiotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects: A Narrative Review.肝细胞癌的碳离子放疗:现状与未来展望:一篇叙述性综述
J Clin Med. 2025 Aug 29;14(17):6107. doi: 10.3390/jcm14176107.
2
Risk Factors of Non-Classic Radiation-Induced Liver Disease (ncRILD) After Intensity-Modulated Radiotherapy in Hepatocellular Carcinoma.肝细胞癌调强放疗后非典型放射性肝病(ncRILD)的危险因素
Cancer Manag Res. 2025 Jun 18;17:1169-1183. doi: 10.2147/CMAR.S539527. eCollection 2025.
3
Dynamic Neutrophil-to-Lymphocyte Ratio at 3-4 weeks of Intensity-Modulated Radiotherapy Combined with Normal Liver Volume Predicts Radiation-Induced Hepatic Toxicity in Hepatocellular Carcinoma: A Retrospective Study.
调强放疗联合正常肝脏体积3 - 4周时的动态中性粒细胞与淋巴细胞比值预测肝细胞癌放疗所致肝毒性:一项回顾性研究
J Inflamm Res. 2025 Jun 17;18:7879-7892. doi: 10.2147/JIR.S523065. eCollection 2025.
4
Radiomics of Dynamic Contrast-Enhanced MRI for Predicting Radiation-Induced Hepatic Toxicity After Intensity Modulated Radiotherapy for Hepatocellular Carcinoma: A Machine Learning Predictive Model Based on the SHAP Methodology.动态对比增强磁共振成像的影像组学用于预测肝细胞癌调强放疗后放射性肝毒性:基于SHAP方法的机器学习预测模型
J Hepatocell Carcinoma. 2025 May 17;12:999-1015. doi: 10.2147/JHC.S523448. eCollection 2025.
5
Liver injury and recovery following radiation therapy for hepatocellular carcinoma: insights from functional liver imaging.肝细胞癌放射治疗后的肝脏损伤与恢复:基于功能性肝脏成像的见解
Hepatoma Res. 2024;10. doi: 10.20517/2394-5079.2024.27. Epub 2024 Sep 8.
6
Liver quad culture chip as a model for radiation injury research.肝四元培养芯片作为辐射损伤研究的模型
Sci Rep. 2025 Apr 11;15(1):12414. doi: 10.1038/s41598-025-96140-1.
7
Treatment of intermediate-to-advanced unresectable hepatocellular carcinoma is shifting toward a multidisciplinary strategy that includes multiple modalities as needed.中晚期不可切除肝细胞癌的治疗正朝着多学科策略转变,该策略根据需要包括多种治疗方式。
World J Gastroenterol. 2025 Mar 14;31(10):103420. doi: 10.3748/wjg.v31.i10.103420.
8
Current Insights into Molecular Mechanisms and Potential Biomarkers for Treating Radiation-Induced Liver Damage.当前对治疗放射性肝损伤的分子机制和潜在生物标志物的深入了解。
Cells. 2024 Sep 16;13(18):1560. doi: 10.3390/cells13181560.
9
Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial.SBRT 联合替雷利珠单抗和 IBI305 治疗晚期 HCC 患者的疗效和安全性:一项失败的免疫治疗的 2 期临床试验研究方案。
BMJ Open. 2024 Jun 10;14(6):e077903. doi: 10.1136/bmjopen-2023-077903.
10
Microinvasion in hepatocellular carcinoma: predictive factor and application for definition of clinical target volume for radiotherapy.肝细胞癌的微侵袭:预测因素及其在放射治疗临床靶区定义中的应用。
World J Surg Oncol. 2024 May 8;22(1):125. doi: 10.1186/s12957-024-03399-1.